The Asp-glutamate transporter SLC1A3 is closely associated with the effect of ETC inhibitors, and the SLC1A3 site is amplified in subclusters of non-glial epithelial tumors and thus against aspartic restriction.92 Sun et al. found that SLC1A3 promotes breast cancer cells to L-asparaginase (ASNase) resistance. Here, SLC1A3 is linked to breast cancer.